N/A
Manufactured by Kyowa Kirin, Inc.
10,519 FDA adverse event reports analyzed
Last updated: 2026-04-15
BUROSUMAB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Kyowa Kirin, Inc.. The most commonly reported adverse reactions for BUROSUMAB include INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION, PRODUCT DOSE OMISSION ISSUE, BLOOD PHOSPHORUS DECREASED, PAIN, ARTHRALGIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BUROSUMAB.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 10,519 FDA FAERS reports that mention BUROSUMAB. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION, PRODUCT DOSE OMISSION ISSUE, BLOOD PHOSPHORUS DECREASED, PAIN, ARTHRALGIA, PAIN IN EXTREMITY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Kyowa Kirin, Inc. in connection with BUROSUMAB. Always verify the specific product and NDC with your pharmacist.